The goal of this proposal is to establish a """"""""Center for Cancer Experimental Therapeutics"""""""" in the State of Kansas. Three state institutions combine their resources and faculty to establish a Center to mentor junior faculty in cancer-related research and novel infrastructure needed for experimentation at the interface between chemistry and biology. Matching funds provided by the University of Kansas (KU) and the Kansas Technology Enterprise Corporation (KTEC) together with NIH-COBRE support will result in the establishment of unique core facilities needed to identify novel bioactive compounds that will be useful basic biomedical research tools, and potential therapeutic agents. A strong tradition in medicinal chemistry at KU, relationships with expansion and turnover of junior faculty in basic-biomedical research over the next five years makes Kansas a logical site for establishing a Center for research in experimental therapeutics. Funds are requested for the support of five projects in which junior faculty and one successful senior faculty not previously funded by NIH serve as P.I.s. These faculty are partnered with competitiveness of future recruits, and a competitive program for the obtainment of large-scale equipment and facilities support will be established. Two Cores will be established and operated by an experienced group of investigators with expertise in the areas of combinatorial chemistry, cell and molecular biology, biochemistry, cancer cell biology, and the development of novel bioassays for compound and cellular target identification. The combination of expertise for the generation and analysis of novel compounds, together with that for the development of bioassays for screening, offers a unique opportunity for joining two research areas into two combined effort. The Cores will work with new junior faculty to screen compound libraries from the National Cancer Institute repositories, those from commercial sources, and those generated on-site, for identification of reagents that will enhance their research.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR015563-03
Application #
6529888
Study Section
Special Emphasis Panel (ZRR1-RCMI-2 (02))
Program Officer
Sayre, Michael
Project Start
2000-09-30
Project End
2005-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
3
Fiscal Year
2002
Total Cost
$1,980,477
Indirect Cost
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072933393
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Subramanian, Chitra; Grogan, Patrick T; Opipari, Valerie P et al. (2018) Novel natural withanolides induce apoptosis and inhibit migration of neuroblastoma cells through down regulation of N-myc and suppression of Akt/mTOR/NF-?B activation. Oncotarget 9:14509-14523
Ishiguro, Susumu; Kawabata, Atsushi; Zulbaran-Rojas, Alejandro et al. (2018) Co-treatment with a C1B5 peptide of protein kinase C? and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation. Biochem Biophys Res Commun 495:962-968
He, Chenchen; Duan, Shaofeng; Dong, Liang et al. (2017) Characterization of a novel p110?-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. Prostate 77:1187-1198
White, Peter T; Subramanian, Chitra; Zhu, Qing et al. (2016) Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery 159:142-51
Ohta, Naomi; Ishiguro, Susumu; Kawabata, Atsushi et al. (2015) Human umbilical cord matrix mesenchymal stem cells suppress the growth of breast cancer by expression of tumor suppressor genes. PLoS One 10:e0123756
Li, Benyi; Thrasher, James Brantley; Terranova, Paul (2015) Glycogen synthase kinase-3: a potential preventive target for prostate cancer management. Urol Oncol 33:456-63
Ishiguro, Susumu; Yoshimura, Kiyoshi; Tsunedomi, Ryouichi et al. (2015) Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): a novel AT2R agonist effectively attenuates growth of PDAC grafts in mice. Cancer Biol Ther 16:307-16
Li, Benyi; Sun, Aijing; Jiang, Wencong et al. (2014) PI-3 kinase p110?: a therapeutic target in advanced prostate cancers. Am J Clin Exp Urol 2:188-98
Bibis, Stergios S; Dahlstrom, Kelly; Zhu, Tongtong et al. (2014) Characterization of Leishmania major phosphatidylethanolamine methyltransferases LmjPEM1 and LmjPEM2 and their inhibition by choline analogs. Mol Biochem Parasitol 196:90-9
Subramanian, Chitra; Zhang, Huaping; Gallagher, Robert et al. (2014) Withanolides are potent novel targeted therapeutic agents against adrenocortical carcinomas. World J Surg 38:1343-52

Showing the most recent 10 out of 240 publications